Yahoo Web Search

Search results

  1. Apr 17, 2017 · Luis A. Diaz, MD, has been named the Head of the Division of Solid Tumor Oncology in the Department of Medicine at Memorial Sloan Kettering (MSK). An accomplished physician, pioneering researcher, and leader in the field of clinical oncology, Dr. Diaz most recently served as an associate professor of oncology at the Johns Hopkins University ...

  2. Sep 4, 2014 · Dr. Luis Diaz: Marrying Cancer Genomics with Immunotherapy. “It worked better than our wildest dreams,” Dr. Diaz said of a therapeutic approach that uses a tumor biomarker to identify patients likely to respond to immunotherapy.

  3. Luis Diaz, MD, is the Head of the Division of Solid Tumor Oncology at Memorial Sloan Kettering Cancer Center in New York. Dr. Diaz led the landmark study of PD-1 blockade in MSI CRC, the first successful trial of immunotherapy in CRC, which has led to pembrolizumab receiving FDA breakthrough designation in treatment-refractory colorectal cancer ...

  4. Jul 6, 2023 · Oncologist Luis Diaz Jr., at Memorial Sloan Kettering, achieved a breakthrough in cancer treatment. He focused on tumors with MMR deficiency.

  5. Jan 26, 2024 · therapy in patients with mismatch repair deficient tumors. He is member of the National Academy of Medicine and in 2021, Dr. Diaz was appointe.

  6. People also ask

  7. Jun 13, 2017 · Luis A. Diaz, MD, has been named the Head of the Division of Solid Tumor Oncology in the Department of Medicine at Memorial Sloan Kettering (MSK).

  1. People also search for